Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2026; 32(46): 121313
Published online Dec 14, 2026. doi: 10.3748/wjg.121313
Published online Dec 14, 2026. doi: 10.3748/wjg.121313
Impact of glucagon-like peptide-1 receptor agonists on bowel preparation quality for colonoscopy in type 2 diabetes
Hyun Jung Park, Young Eun Oh, Minjee Kim, Ji Eun Kim, Sung Noh Hong, Byung-Hoon Min, Young-Ho Kim, Dong Kyung Chang, Tae-Se Kim, Eun Ran Kim, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea
Sang Ah Chi, Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, South Korea
Co-first authors: Hyun Jung Park and Young Eun Oh.
Co-corresponding authors: Tae-Se Kim and Eun Ran Kim.
Author contributions: Park HJ and Oh YE contributed equally to this work and are co-first authors; Park HJ and Oh YE drafted the manuscript; Park HJ, Oh YE, Kim TS, and Kim ER contributed to the conception and design of the study; Park HJ, Oh YE, Chi SA, Kim TS, and Kim ER contributed to the analysis and interpretation of the data; Kim M, Kim JE, Hong SN, Min BH, Kim YH, and Chang DK contributed to data acquisition and critically revised the manuscript for important intellectual content; Kim TS and Kim ER contributed equally as co-corresponding authors. All authors reviewed and approved the final manuscript and agree to be accountable for all aspects of the work.
AI contribution statement: No AI tools were used in a manner that requires disclosure under the AI tool usage policy.
Institutional review board statement: This study was approved by the Institutional Review Board of Samsung Medical Center, No. 2025-02-025.
Informed consent statement: The requirement for written informed consent was waived by the Institutional Review Board given the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Eun Ran Kim, MD, PhD, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. er.kim@samsung.com
Received: April 7, 2026
Revised: June 11, 2026
Accepted: June 30, 2026
Published online: December 14, 2026
Processing time: 198 Days and 15.6 Hours
Revised: June 11, 2026
Accepted: June 30, 2026
Published online: December 14, 2026
Processing time: 198 Days and 15.6 Hours
Core Tip
Core Tip: Glucagon-like peptide-1 receptor agonists are increasingly used in patients with type 2 diabetes mellitus; however, their effect on bowel preparation quality before colonoscopy remains unclear. In this propensity score-matched cohort study, glucagon-like peptide-1 receptor agonist use was associated with a high risk of inadequate bowel preparation, particularly in the right colon. These findings highlight a practical issue in endoscopic practice and suggest that optimized bowel pre